Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Insight into the mechanism of laquinimod action.
Interferon-β-1b: a review of its use in multiple sclerosis.
Molecular characterization of a peripheral receptor for cannabinoids.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Opinion: Sex inclusion in basic research drives discovery.
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
NOVANTRONE. mitoXANTRONE for injection concentrate
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Studying both sexes: a guiding principle for biomedicine.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.

Pages